Zydus Lifesciences Shares Plunge 3% Despite Receiving USFDA Approval – Equitypandit
Shares of Zydus Lifesciences Ltd were trading 3% lower on 22 May despite the company receiving final approval from the US health authorities to produce and sell 300 mg and 450 mg doses of Theophylline Extended-Release Tablets. The business informed the stock exchanges that the tablets can be used to treat COPD, also known as chronic…